Výsledky vyhledávání - "L, Vaccarello"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

Autor: Virginia L. Filiaci, Gini F. Fleming, Thomas J. Herzog, J. Sorosky, Rex C. Bentley, L. Vaccarello, Holly H. Gallion

Publikováno v: Annals of Oncology. 15:1173-1178

Background: This study was performed to determine whether 24-h paclitaxel plus doxorubicin and filgrastim was superior to cisplatin plus doxorubicin in patients with endometrial cancer with respect to response, progression-free survival (PFS) and ove

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32075d9b4423ef927dbe3820296ea5ed
https://doi.org/10.1093/annonc/mdh316

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study

Autor: George A. Omura, David G. Mutch, M L Berman, J A Blessing, D L Clarke-Pearson, L Vaccarello, B Anderson

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 15(1)

PURPOSE Cisplatin, mitolactol (dibromodulcitol), and ifosfamide have been the most active single agents in squamous carcinoma of the cervix identified so far by the Gynecologic Oncology Group (GOG). Combinations of cisplatin plus ifosfamide and cispl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9921d482c5828b765a79d31e7b78199
https://pubmed.ncbi.nlm.nih.gov/8996138

Zobrazit plný text záznamu

Second-look laparotomy in epithelial ovarian cancer

Autor: L J, Copeland, L, Vaccarello, G S, Lewandowski

Publikováno v: Obstetrics and gynecology clinics of North America. 21(1)

The absence of a reliable noninvasive means of detecting persistent clinically occult ovarian cancer is the basis for performing repetitive operative procedures, usually called a second-look. Although controversy persists regarding whether second-loo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2dc6648ab36aaaf68d70420849d342db
https://pubmed.ncbi.nlm.nih.gov/8015761

Zobrazit plný text záznamu

Presentation and management of carcinosarcoma of the uterus

Autor: L, Vaccarello, J P, Curtin

Publikováno v: Oncology (Williston Park, N.Y.). 6(5)

Carcinosarcoma of the uterus is an uncommon tumor composed of epithelial and mesenchymal components. The incidence is higher in blacks and increases with age. It most commonly presents with postmenopausal bleeding or as a prolapsing, polypoid uterine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8c44c9013856c610d98ff873eb8f6d86
https://pubmed.ncbi.nlm.nih.gov/1534676

Zobrazit plný text záznamu

Magnetic resonance imaging to diagnose a müllerian anomaly during pregnancy

Autor: J L, Kelley, R P, Edwards, P, Wozney, L, Vaccarello, S A, Laifer

Publikováno v: Obstetrics and gynecology. 75(3 Pt 2)

An adolescent woman presented with a paravaginal mass during pregnancy. Magnetic resonance imaging was useful in diagnosing a müllerian anomaly consisting of a double uterus and cervix and blind vaginal pouch. Magnetic resonance imaging can be an im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4dd90b5700b373784ecd7a5b6874ffb5
https://pubmed.ncbi.nlm.nih.gov/2304728

Zobrazit plný text záznamu

A phase II trial of weekly one hour paclitaxel as second-line therapy for endometrial and cervical cancer

Autor: G. Lowendowski, A. A. Elbendary, L. Vaccarello, Howard D. Homesley

Publikováno v: Journal of Clinical Oncology. 24:15013-15013

15013 Background: The antitumor activity of other regimens of paclitaxel (from Bristol-Myers Squibb Oncology, Bristol-Myers Squibb Company, Princeton, NJ, U. S. A.) has been identified in both cervical and endometrial cancer. A less toxic and better

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2ab9cca056457d9a7e4533cf7c0cd74
https://doi.org/10.1200/jco.2006.24.18_suppl.15013

Zobrazit plný text záznamu

A preliminary report of a phase II study of weekly topotecan in platinum-sensitive recurrent ovarian and peritoneal carcinoma

Autor: G. Lewandowski, M. Rodriguez, M. W. Method, R. H. Ansari, L. Vaccarello

Publikováno v: ResearcherID

5063 Background: Topotecan 1.5 mg/m2 on days 1 through 5 of a 21-day cycle is an established chemotherapeutic regimen for recurrent ovarian cancer. However, noncumulative myelosuppression has limited topotecan's use in some patients (pts). Topotecan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a2abfd0024a2d884a6b7f8f0df5d094
https://doi.org/10.1200/jco.2004.22.90140.5063

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání